Fig. 1.

TNF, sodium salicylate, and cycloheximide responses in normal and leukemic cells. MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium] proliferation/cytotoxicity assays were performed on primary lymphocytes (a and d) and TF-1 (b, e, g–j), and K562 (c and f) leukemia cells treated with TNF (a–c), sodium salicylate (d–f, i, and j) or cycloheximide (g and h) stimulation. Except where indicated, cells were pretreated with 1 ng/ml GM-CSF or 50 ng/ml TNF for 24 h before stimulation. Data represent the means ± SEM, n = 4 (n = 3 for i and j).